Q-omics provides the consensus-scored NPR2 profile across patient tissues and cancer cell-line models. NPR2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NPR2 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, NPR2 RNA expression shows 19,627 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, BLCA, and UVM as cancer lineages where NPR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPR2 survival associations across molecular data types. NPR2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPR2 RNA expression–survival associations across cancer types. High NPR2 expression shows unfavorable associations in UVM, COAD and KIRC, but favorable associations in UCS, KIRP and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NPR2 RNA expression.
This table summarizes NPR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NPR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPR2 shows lower tumor expression in BLCA, LUAD, THCA, UCEC and BRCA and higher tumor expression in LIHC. The BLCA box plot shows higher NPR2 RNA expression in normal versus tumor tissue (log2 FC = −2.345, t-test p < 0.001).
This table shows molecular features associated with NPR2 in patient tissues and cancer cell lines. In patient samples, NPR2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
